Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTA-AML
NCT07754799Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2029
01
Overview
Phase 2, randomised, open-label trial of venetoclax in acute myeloid leukemia (AML) (4 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Event-free survival at 3 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07754799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07754799.